MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak — Biomedical Watch V2

Essais liés10clinical trials

VilleWroclawlocalisation

PaysPolandlocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03832998

Ouvrir le site du centre

Essais cliniques associés

10

Molécule	Indication / population	Phase	NCT	Titre	Statut
Erenumab Dose 1	Migraine	Phase 3	NCT03832998	OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	COMPLETED
Rimegepant 75mg daily dosing	Migraine	Phase 4	NCT05217927	Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens	COMPLETED
Erenumab	Migraine	Phase 4	NCT04252742	EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine	COMPLETED
Eptinezumab	Migraine	Phase 3	NCT05897320	PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine	RECRUITING
Erenumab Dose 1	Migraine	Phase 3	NCT03836040	OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine	ACTIVE_NOT_RECRUITING
Eptinezumab	Migraine	Phase 3	NCT05164172	REJOIN — A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine	RECRUITING
Eptinezumab	Migraine	Phase 3	NCT04965675	PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine	RECRUITING
Corabotase	Migraine	Phase 2	NCT06625060	MERANTI — A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults	ACTIVE_NOT_RECRUITING
Rimegepant	Migraine	Phase 3	NCT05156398	Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects	RECRUITING
Rimegepant/BHV3000	Migraine	Phase 3	NCT04649242	Randomized Study in Children and Adolescents With Migraine: Acute Treatment	RECRUITING